Senores Pharmaceuticals Limited (SPL) has successfully acquired a portfolio of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy’s Laboratories, marking a significant expansion of its product offerings in the U.S. market. The acquisition was executed through SPL’s wholly-owned U.S. subsidiary, Senores Pharmaceuticals, Inc. (SPI).
Of the 14 ANDAs acquired, 13 have already received approval from the U.S. Food and Drug Administration (USFDA), while one is pending approval. The estimated market opportunity of these products stands at approximately $421 million (MAT December 2024), according to IQVIA data, and $1.13 billion (MAT September 2024), per specialty data aggregator Symphony.
The acquisition is being funded through proceeds raised via Senores Pharmaceuticals’ Initial Public Offering (IPO), aligning with the company’s stated objectives in its Red Herring Prospectus.
Strategic Implications of the Acquisition
Senores Pharmaceuticals’ Managing Director, Swapnil Shah, emphasized the significance of the acquisition, stating:
“We are delighted to acquire this diverse portfolio of products from Dr. Reddy’s, which spans multiple therapeutic areas with growing demand. The portfolio includes both controlled substances and general pharmaceutical products, catering to government contracts, retail distribution, and specialty clinics. This move substantially strengthens our product range in the U.S. while also opening up opportunities in other regulated and semi-regulated markets worldwide.”
With this acquisition, Senores Pharmaceuticals’ U.S. presence will be significantly reinforced, adding to its existing portfolio of 27 ANDAs and 21 CMO/CDMO commercial products currently permitted for distribution in the country.
Senores’ Global Presence and Growth Trajectory
Senores Pharmaceuticals has an extensive global footprint, with a strong presence in the U.S., Canada, and emerging markets. The company is engaged in the development and manufacturing of complex generics and critical care injectables. It operates:
-
Two formulation manufacturing facilities:
- One in Atlanta, USA, which is USFDA-approved and DEA/BAA-compliant.
- Another in Chhatral, Ahmedabad, India, certified by WHO-GMP for emerging markets.
-
Two Active Pharmaceutical Ingredient (API) facilities in Ahmedabad, India.
The company has over 260 product registrations and 530 product applications globally and has secured regulatory approvals from more than 10 countries.
